New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base - capsule - 10 mg - active: atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base excipient: dimeticone gelatin pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - atomoxetine hydrochloride eqv atomoxetine - capsule - 10 mg - atomoxetine hydrochloride eqv atomoxetine 10 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - atomoxetine hydrochloride - oral capsule - 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 11.43 mg (equivalent: atomoxetine, qty 10 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; gelatin; sodium lauryl sulfate; dimeticone 350; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine hydrochloride 10 mg - strattera is indicated for the treatment of attention–deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)]. a diagnosis of adhd (dsm–iv) implies the presence of hyperactive–impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic test. adequate diagnosis re

Malta - English - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - atomoxetine - hard capsule - atomoxetine 10 mg - psychoanaleptics

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

eli lilly (s.a.) (pty) ltd - capsules - see ingredients - each capsule contains atomoxetine hydrochloride equivalent to atomoxetine 10,0 mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eli lilly benelux sa-nv - atomoxetine hydrochloride 11,43 mg - eq. atomoxetine 10 mg - capsule, hard - 10 mg - atomoxetine hydrochloride 11.43 mg - atomoxetine

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الادوية العربي - the arab drug store p.s.c - atomoxetine 10 mg - 10 mg

United States - English - NLM (National Library of Medicine)

eli lilly and company - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 10 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)] . a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic test. adequate diagnosis r